🤝 Not all microbes are rivals — some collaborate
Recent research shows that Aspergillus fumigatus and Pseudomonas aeruginosa can cooperate, particularly in people with weakened lungs or structural damage (e.g. from bronchiectasis, CF, or CPA).
Examples of how they interact:
-
Pseudomonas produces toxins (phenazines) that sometimes stimulate Aspergillus growth in low doses
-
Aspergillus produces substances like gliotoxin that weaken immune responses and protect both microbes
-
Both can form mixed biofilms, making them more drug-resistant and more inflammatory
⚠️ Clinical implications:
Coinfection with Aspergillus and Pseudomonas is associated with:
-
Worse lung function in CF, bronchiectasis, CPA
-
More frequent exacerbations and hospital admissions
-
Longer recovery times and lower quality of life
🧠 Why is this important for treatment?
Doctors are now:
-
Testing for multiple microbes during exacerbations
-
Using combination therapy — antifungals and antibiotics together
-
Supporting the immune system with:
-
Airway clearance
-
Nutrition
-
Steroid balancing (not too much, not too little)
-
🧬 New tools on the horizon:
-
Drugs that block microbial signalling (quorum sensing)
-
Microbiome profiling to predict flare-ups
-
Biofilm-dissolving agents in development
-
Inhaled antifungals under trial (e.g. opelconazole)
🌟 Final Summary: A Shift in Perspective
| Old Approach | New, Holistic Approach |
|---|---|
| Target a single infection | Understand the whole lung ecosystem |
| Treat only during active infection | Focus on prevention, balance, resilience |
| One-size-fits-all antibiotic use | Tailored therapy, minimise microbiome damage |
| Ignore biofilms | Disrupt biofilms and support mucus clearance |
| Fungal and bacterial issues separate | Recognise synergy and co-infection |
Latest News posts
News archive